<DOC>
<DOCNO>EP-0627006</DOCNO> 
<TEXT>
<INVENTION-TITLE>
HYBRID DNA THAT CODES FOR A SUBUNIT OF A BACTERIAL TOXIN WITH A HEMOLYSIN
</INVENTION-TITLE>
<CLASSIFICATIONS>C07K14195	A61K3900	C12N121	A61K39112	A61K3900	A61P3104	C07K1425	C07K1900	C07K1900	C12N1509	C12N1509	C12N121	A61K39112	C07K14195	A61P3100	C07K14245	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07K	A61K	C12N	A61K	A61K	A61P	C07K	C07K	C07K	C12N	C12N	C12N	A61K	C07K	A61P	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07K14	A61K39	C12N1	A61K39	A61K39	A61P31	C07K14	C07K19	C07K19	C12N15	C12N15	C12N1	A61K39	C07K14	A61P31	C07K14	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
BIOTECHNOLOG FORSCHUNG GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
GESELLSCHAFT FUER BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF)
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BRAHMBHATT HIMANSHU
</INVENTOR-NAME>
<INVENTOR-NAME>
SU GUO-FU
</INVENTOR-NAME>
<INVENTOR-NAME>
TIMMIS KENNETH N
</INVENTOR-NAME>
<INVENTOR-NAME>
WEHLAND JUERGEN
</INVENTOR-NAME>
<INVENTOR-NAME>
BRAHMBHATT, HIMANSHU
</INVENTOR-NAME>
<INVENTOR-NAME>
SU, GUO-FU
</INVENTOR-NAME>
<INVENTOR-NAME>
TIMMIS, KENNETH, N.
</INVENTOR-NAME>
<INVENTOR-NAME>
WEHLAND, JUERGEN
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Hybrid DNA, wherein a DNA structure coding for a fragment of 
a bacterial toxin is fused with a C-terminal fragment of a DNA 

structure coding for HlyA (haemolysin), 
characterized
 in that 
the fragment of the bacterial toxin is subunit B of Shigatoxin 

or Shiga-like toxins. 
Hybrid DNA according to claim 1, 
characterized
 in that the 
Shiga-like toxins are SLT-II or SLT-IIv. 
Hybrid DNA according to claim 1 to 2, 
characterized
 in that a 
constitutive promotor or a promotor which can be induced under 

in vivo conditions, is provided in front of both coding DNA 
structures.  

 
Hybrid DNA according to claim 3, 
characterized
 in that a 
promotor for the expression in a 
Salmonella
 strain, especially 

S. typhimurium,
 for example 
S. t.
 aroA
-
 SL3261, is provided in 
front of both coding DNA structures. 
Hybrid DNA according to claim 4, 
characterized
 by a Î²-Lactamase 
promotor of the wild type or as a modification of the 

wild type, wherein the promotor can be provided synthetically or 
not. 
Hybrid DNA according to claim 4, 
characterized
 by an 
Aerobactin promotor. 
Plasmid, 
characterized
 by a hybrid DNA according to any of 
the preceding claims. 
Host strain, 
characterized
 by a plasmid according to claim 7, 
especially a 
Salmonella
 strain, especially 
S. typhimurium,
 for 
example 
S. t.
 aroA
-
 SL3261. 
Oligohybrid peptide, 
characterized
 by subunit B of Shiga 
toxin or Shiga-like toxins, being fused with a C-terminal 

fragment of HlyA. 
Vaccine, consisting of or comprising the oligohybrid peptide 
according to claim 9. 
</CLAIMS>
</TEXT>
</DOC>
